Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895919137> ?p ?o ?g. }
- W2895919137 endingPage "1729" @default.
- W2895919137 startingPage "1729" @default.
- W2895919137 abstract "<h3>Importance</h3> Chimeric and murine anti-G<sub>D2</sub>antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-G<sub>D2</sub>antibody, was constructed. <h3>Objective</h3> To find the maximum-tolerated dose of hu3F8 with granulocyte-macrophage colony-stimulating factor. <h3>Design, Setting, and Participants</h3> This phase 1 clinical trial used a 3 + 3 dose-escalation design in a single referral center (Memorial Sloan Kettering Cancer Center, New York, New York). Participants were enrolled from December 24, 2012, through May 3, 2016, with follow-up and analyses through February 28, 2018. Eligibility criteria included older than 1 year and resistant or recurrent neuroblastoma regardless of the number or kinds of prior treatments. All 57 participants met the eligibility criteria, received treatment according to the protocol, and were included in all analyses. <h3>Interventions</h3> Treatment cycles were monthly, if human antihuman antibody remained negative. Each cycle comprised hu3F8 infused intravenously for 30 minutes on Monday, Wednesday, and Friday as well as granulocyte-macrophage colony-stimulating factor administered subcutaneously daily from 5 days before infusion through the last day of infusion. After cycle 2, hu3F8 was increased to the highest dose level that had been confirmed as safe. <h3>Main Outcomes and Measures</h3> Toxicity, pharmacokinetics, immunogenicity, and disease response. <h3>Results</h3> Of the 57 participants, 34 (60%) were male and 23 (40%) were female (male-to-female ratio of 1.5), with a median (range) age of 6.8 (2.4-31.3) years at enrollment and a median (range) time of 3.1 (0.6-9.0) years since initial chemotherapy. Participants received a median (range) of 4 (1-15) cycles. Treatment was outpatient with reversible neuropathic pain and without unexpected toxic effects. No maximum-tolerated dose was identified. Dose escalation was associated with increased serum levels and proceeded through dosage of 9.6 mg/kg/cycle (approximately 288 mg/m<sup>2</sup>), which is more than 2.5 times higher than the standard dosage of 75 mg/m<sup>2</sup>/cycle or 100 mg/m<sup>2</sup>/cycle of dinutuximab and m3F8. Human antihuman antibody positivity developed in 5 of 57 patients (9%) after cycle 1, including in 1 of 10 patients (10%) not previously treated with anti-G<sub>D2</sub>antibody and in 4 of 47 patients (9%) previously exposed to 1 or 2 anti-G<sub>D2</sub>antibodies. Antineuroblastoma activity included major responses associated with higher dosing and prolonged progression-free survival despite a history of relapses. <h3>Conclusions and Relevance</h3> This phase 1 clinical trial found hu3F8 to be associated with modest toxic effects, low immunogenicity, and substantial antineuroblastoma activity; phase 2 trials are in progress. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT01757626" @default.
- W2895919137 created "2018-10-26" @default.
- W2895919137 creator A5016432846 @default.
- W2895919137 creator A5026950879 @default.
- W2895919137 creator A5043729995 @default.
- W2895919137 creator A5050680844 @default.
- W2895919137 creator A5078376796 @default.
- W2895919137 creator A5083817841 @default.
- W2895919137 date "2018-12-01" @default.
- W2895919137 modified "2023-10-01" @default.
- W2895919137 title "Humanized 3F8 Anti-G<sub>D2</sub>Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma" @default.
- W2895919137 cites W1511277433 @default.
- W2895919137 cites W1519295343 @default.
- W2895919137 cites W1575002436 @default.
- W2895919137 cites W1587504796 @default.
- W2895919137 cites W1901831739 @default.
- W2895919137 cites W1993940563 @default.
- W2895919137 cites W2034015697 @default.
- W2895919137 cites W2061770965 @default.
- W2895919137 cites W2085435245 @default.
- W2895919137 cites W2098147098 @default.
- W2895919137 cites W2102739282 @default.
- W2895919137 cites W2110340629 @default.
- W2895919137 cites W2114993851 @default.
- W2895919137 cites W2122070299 @default.
- W2895919137 cites W2122286507 @default.
- W2895919137 cites W2130465135 @default.
- W2895919137 cites W2130686884 @default.
- W2895919137 cites W2133832975 @default.
- W2895919137 cites W2140839532 @default.
- W2895919137 cites W2151310238 @default.
- W2895919137 cites W2155614959 @default.
- W2895919137 cites W2293124958 @default.
- W2895919137 cites W2331868380 @default.
- W2895919137 cites W2611071372 @default.
- W2895919137 cites W2740339041 @default.
- W2895919137 cites W2741106632 @default.
- W2895919137 cites W4207058970 @default.
- W2895919137 doi "https://doi.org/10.1001/jamaoncol.2018.4005" @default.
- W2895919137 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6440722" @default.
- W2895919137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326045" @default.
- W2895919137 hasPublicationYear "2018" @default.
- W2895919137 type Work @default.
- W2895919137 sameAs 2895919137 @default.
- W2895919137 citedByCount "73" @default.
- W2895919137 countsByYear W28959191372019 @default.
- W2895919137 countsByYear W28959191372020 @default.
- W2895919137 countsByYear W28959191372021 @default.
- W2895919137 countsByYear W28959191372022 @default.
- W2895919137 countsByYear W28959191372023 @default.
- W2895919137 crossrefType "journal-article" @default.
- W2895919137 hasAuthorship W2895919137A5016432846 @default.
- W2895919137 hasAuthorship W2895919137A5026950879 @default.
- W2895919137 hasAuthorship W2895919137A5043729995 @default.
- W2895919137 hasAuthorship W2895919137A5050680844 @default.
- W2895919137 hasAuthorship W2895919137A5078376796 @default.
- W2895919137 hasAuthorship W2895919137A5083817841 @default.
- W2895919137 hasBestOaLocation W28959191371 @default.
- W2895919137 hasConcept C112705442 @default.
- W2895919137 hasConcept C126322002 @default.
- W2895919137 hasConcept C143998085 @default.
- W2895919137 hasConcept C159654299 @default.
- W2895919137 hasConcept C203014093 @default.
- W2895919137 hasConcept C2777288759 @default.
- W2895919137 hasConcept C2777478134 @default.
- W2895919137 hasConcept C2778690821 @default.
- W2895919137 hasConcept C2780868878 @default.
- W2895919137 hasConcept C71924100 @default.
- W2895919137 hasConcept C90924648 @default.
- W2895919137 hasConceptScore W2895919137C112705442 @default.
- W2895919137 hasConceptScore W2895919137C126322002 @default.
- W2895919137 hasConceptScore W2895919137C143998085 @default.
- W2895919137 hasConceptScore W2895919137C159654299 @default.
- W2895919137 hasConceptScore W2895919137C203014093 @default.
- W2895919137 hasConceptScore W2895919137C2777288759 @default.
- W2895919137 hasConceptScore W2895919137C2777478134 @default.
- W2895919137 hasConceptScore W2895919137C2778690821 @default.
- W2895919137 hasConceptScore W2895919137C2780868878 @default.
- W2895919137 hasConceptScore W2895919137C71924100 @default.
- W2895919137 hasConceptScore W2895919137C90924648 @default.
- W2895919137 hasIssue "12" @default.
- W2895919137 hasLocation W28959191371 @default.
- W2895919137 hasLocation W28959191372 @default.
- W2895919137 hasLocation W28959191373 @default.
- W2895919137 hasLocation W28959191374 @default.
- W2895919137 hasOpenAccess W2895919137 @default.
- W2895919137 hasPrimaryLocation W28959191371 @default.
- W2895919137 hasRelatedWork W1934038313 @default.
- W2895919137 hasRelatedWork W1964391114 @default.
- W2895919137 hasRelatedWork W1980772934 @default.
- W2895919137 hasRelatedWork W1990335353 @default.
- W2895919137 hasRelatedWork W2065005216 @default.
- W2895919137 hasRelatedWork W2154372624 @default.
- W2895919137 hasRelatedWork W2377624422 @default.
- W2895919137 hasRelatedWork W2387950569 @default.
- W2895919137 hasRelatedWork W2803203200 @default.
- W2895919137 hasRelatedWork W3150151478 @default.
- W2895919137 hasVolume "4" @default.